InvestorsHub Logo
Followers 11
Posts 908
Boards Moderated 0
Alias Born 04/01/2014

Re: BBalllegend post# 192295

Wednesday, 12/13/2023 4:03:27 PM

Wednesday, December 13, 2023 4:03:27 PM

Post# of 200355
I don't recall seeing it being reported that Barry went to Africa.

"The previously announced Clinical trials on Diabetes in Bulgaria, designed to investigate the impact of ITV-1 on blood sugar and the most important indicator of Glycosylated Hemoglobin blood glucose level, remain in progress. Shortly after the sale of VIRO to SAGA, Barry Kostiner, CEO of SAGA accompanied Diana and Harry Zhabilov, CEO and CSO respectively of Virogenetics, Inc., to Bulgaria where he toured the manufacturing facilities of ITV-1 and IPF Immune®. He also met with the former Prime Minister of Bulgaria and several of the advisors, service providers and supporters that VIRO has developed over the years."

"Barry Kostiner commented, "My trip to Bulgaria was inspiring. Meeting members of the VIRO management team and their premier manufacturing and clinical trial vendors deepened my appreciation for the technology and opportunity ahead. An affiliate of GLD, the former sponsor of Sagaliam, recently filed a lawsuit asserting that the transaction with VIRO and BGEN disenfranchises GLD of its voting rights. We intend to vigorously defend Sagaliam against the lawsuit. We are committed to protecting the interests of our shareholders and believe that the lawsuit is without merit, particularly given that no shareholder would benefit from the dissolution of Sagaliam. This transaction benefits all shareholders and will provide a path to the capital needed to bring multiple valuable therapies to commercialization, in addition to benefiting disadvantaged communities in Africa and around the world that suffer from the high costs and lack of access to existing therapies.""

https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Inc-Files-Amended-December-31-2022-OTC-Report-with-Audited-Financials-and-Unaudited-September-30-2023-Quarter?id=422061